Studies to Prevent Metastasis May Lead to Treatments for Metastatic Breast Cancer
By Joan Mancuso
This year's annual National Breast Cancer Coalition's Leadership Summit and Lobby Day included informative sessions on metastasis research. One session about preventing breast cancer from metastasizing also holds promise for developing treatments to work against active metastatic breast cancer lesions. The session, which was titled, After 25 Years, What Do We Really Know About Preventing Metastasis? was presented in part by Dr. Cyrus Ghajar of Fred Hutchinson Cancer Center in Seattle.
Kisqali (ribociclib, LEE011) receives FDA approval as first-line treatment for HR+/HER2- metastatic breast cancer in combination with any aromatase inhibitor
On March 13, 2017, the U.S. Food and Drug Administration approved ribociclib (KISQALI, Novartis Pharmaceuticals Corp.), a cyclin-dependent kinase 4/6 inhibitor (CDK-4/6), in combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.
According to the FDA, Approval was based on a randomized, double-blind, placebo-controlled, international clinical trial (MONALEESA-2), in post-menopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer who received no prior therapy for advanced disease,